Literature DB >> 20395397

Appearance of the pituitary factor Pit-1 increases chromatin remodeling at hypersensitive site III in the human GH locus.

Xiaoyang Yang1, Yan Jin, Peter A Cattini.   

Abstract

Expression of pituitary and placental members of the human GH and chorionic somatomammotropin (CS) gene family is directed by an upstream remote locus control region (LCR). Pituitary-specific expression of GH requires direct binding of Pit-1 (listed as POU1F1 in the HUGO database) to sequences marked by a hypersensitive site (HS) region (HS I/II) 14.6 kb upstream of the GH-N gene (listed as GH1 in the HUGO database). We used human embryonic kidney 293 (HEK293) cells overexpressing wild-type and mutant Pit-1 proteins as a model system to gain insight into the mechanism by which Pit-1 gains access to the GH LCR. Addition of Pit-1 to these cells increased DNA accessibility at HS III, located 28 kb upstream of the human GH-N gene, in a POU homeodomain-dependent manner, as reflected by effects on histone hyperacetylation and RNA polymerase II activity. Direct binding of Pit-1 to HS III sequences is not supported. However, the potential for binding of ETS family members to this region has been demonstrated, and Pit-1 association with this ETS element in HS III sequences requires the POU homeodomain. Also, both ETS1 and ELK1 co-precipitate from human pituitary extracts using two independent sources of Pit-1 antibodies. Finally, overexpression of ELK1 or Pit-1 expression in HEK293 cells increased GH-N RNA levels. However, while ELK1 overexpression also stimulated placental CS RNA levels, the effect of Pit-1 appeared to correlate with ETS factor levels and target GH-N preferentially. These data are consistent with recruitment and an early role for Pit-1 in remodeling of the GH LCR at the constitutively open HS III through protein-protein interaction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20395397      PMCID: PMC5156566          DOI: 10.1677/JME-10-0017

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  32 in total

1.  POU-domain proteins Pit-1 and Oct-1 interact to form a heteromeric complex and can cooperate to induce expression of the prolactin promoter.

Authors:  J W Voss; L Wilson; M G Rosenfeld
Journal:  Genes Dev       Date:  1991-07       Impact factor: 11.361

Review 2.  ETS transcription factors in endocrine systems.

Authors:  Arthur Gutierrez-Hartmann; Dawn L Duval; Andrew P Bradford
Journal:  Trends Endocrinol Metab       Date:  2007-03-26       Impact factor: 12.015

3.  DNase I-hypersensitive sites I and II of the human growth hormone locus control region are a major developmental activator of somatotrope gene expression.

Authors:  I M Bennani-Baïti; S L Asa; D Song; R Iratni; S A Liebhaber; N E Cooke
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

4.  MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data.

Authors:  K Quandt; K Frech; H Karas; E Wingender; T Werner
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

Review 5.  A family of POU-domain and Pit-1 tissue-specific transcription factors in pituitary and neuroendocrine development.

Authors:  H A Ingraham; V R Albert; R P Chen; E B Crenshaw 3d; H P Elsholtz; X He; M S Kapiloff; H J Mangalam; L W Swanson; M N Treacy
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

6.  Hepatocyte nuclear factor-3alpha binding at P sequences of the human growth hormone locus is associated with pituitary repressor function.

Authors:  Lisa D Norquay; Xiaoyang Yang; Yan Jin; Karen A Detillieux; Peter A Cattini
Journal:  Mol Endocrinol       Date:  2005-10-20

7.  The juxtaposition of a promoter with a locus control region transcriptional domain activates gene expression.

Authors:  Yugong Ho; Aleksey Tadevosyan; Stephen A Liebhaber; Nancy E Cooke
Journal:  EMBO Rep       Date:  2008-07-18       Impact factor: 8.807

Review 8.  Activation of the human GH gene cluster: roles for targeted chromatin modification.

Authors:  Yugong Ho; Stephen A Liebhaber; Nancy E Cooke
Journal:  Trends Endocrinol Metab       Date:  2004 Jan-Feb       Impact factor: 12.015

9.  Epigenetic activation of the human growth hormone gene cluster during placental cytotrophoblast differentiation.

Authors:  Atsushi P Kimura; Daria Sizova; Stuart Handwerger; Nancy E Cooke; Stephen A Liebhaber
Journal:  Mol Cell Biol       Date:  2007-07-16       Impact factor: 4.272

10.  Differential placental hormone gene expression during pregnancy in a transgenic mouse containing the human growth hormone/chorionic somatomammotropin locus.

Authors:  Y Jin; S Y Lu; A Fresnoza; K A Detillieux; M L Duckworth; P A Cattini
Journal:  Placenta       Date:  2009-01-24       Impact factor: 3.481

View more
  4 in total

1.  DNase I hypersensitive site II of the human growth hormone locus control region mediates an essential and distinct long-range enhancer function.

Authors:  Margaret R Fleetwood; Yugong Ho; Nancy E Cooke; Stephen A Liebhaber
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  Energy homeostasis targets chromosomal reconfiguration of the human GH1 locus.

Authors:  Hana Vakili; Yan Jin; Peter A Cattini
Journal:  J Clin Invest       Date:  2014-10-08       Impact factor: 14.808

3.  Functional characterization of a human POU1F1 mutation associated with isolated growth hormone deficiency: a novel etiology for IGHD.

Authors:  Marie-Laure Sobrier; Yu-Cheng Tsai; Christelle Pérez; Bruno Leheup; Tahar Bouceba; Philippe Duquesnoy; Bruno Copin; Daria Sizova; Alfredo Penzo; Ben Z Stanger; Nancy E Cooke; Stephen A Liebhaber; Serge Amselem
Journal:  Hum Mol Genet       Date:  2015-11-26       Impact factor: 6.150

4.  Negative regulation of human growth hormone gene expression by insulin is dependent on hypoxia-inducible factor binding in primary non-tumor pituitary cells.

Authors:  Hana Vakili; Yan Jin; Peter A Cattini
Journal:  J Biol Chem       Date:  2012-07-25       Impact factor: 5.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.